Unexpectedly,low hydroxychloroquine concentration enhances DNA-induced immune stimulation in vitro : potential implication in non-compliant patients with SLE

Abstract

Get full access to this article

View all access options for this article.

References

Geraldino-Pardilla

Perel-Winkler

Miceli

, et al. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus 2019; 28: 862–867.

Costedoat-Chalumeau

Amoura

Hulot

, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3284–3290.

Costedoat-Chalumeau

Amoura

Hulot

, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 821–824.

Liu

Fevrier

Goldfien

Hemmerling

Herrinton

. Understanding nonadherence with hydroxychloroquine therapy in systemic lupus erythematosus. J Rheumatol 2019; 46: 1309–1315.

Kuznik

Bencina

Svajger

Jeras

Rozman

Jerala

. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794–4804.

Crow

. Type I interferon in the pathogenesis of lupus. J Immunol 2014; 192: 5459–5468.

Rainsford

Parke

Clifford-Rashotte

Kean

. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 2015; 23: 231–269.

Oliveira-Santos

Verani

Klumb

Albuquerque

. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus 2011; 20: 320–329.

Gustafsson

Walker

Alvan

, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983; 15: 471–479.